12/18
07:09 am
trda
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/18
07:00 am
trda
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/11
10:22 am
trda
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why [Yahoo! Finance]
Low
Report
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why [Yahoo! Finance]
12/7
07:36 am
trda
Entrada Therapeutics, Inc. (NASDAQ: TRDA) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Low
Report
Entrada Therapeutics, Inc. (NASDAQ: TRDA) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
12/6
08:15 am
trda
Entrada Therapeutics, Inc. (NASDAQ: TRDA) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $29.00 price target on the stock.
High
Report
Entrada Therapeutics, Inc. (NASDAQ: TRDA) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $29.00 price target on the stock.
11/25
10:36 am
trda
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
Low
Report
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
11/21
05:35 am
trda
Pompe Disease Pipeline Insight 2024,with Comprehensive Insights for 15+ Companies and 20+ Pipeline Drugs in the Pompe Disease Pipeline Landscape [Yahoo! Finance]
Low
Report
Pompe Disease Pipeline Insight 2024,with Comprehensive Insights for 15+ Companies and 20+ Pipeline Drugs in the Pompe Disease Pipeline Landscape [Yahoo! Finance]
11/6
09:16 am
trda
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $25.00 to $28.00. They now have an "outperform" rating on the stock.
Low
Report
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $25.00 to $28.00. They now have an "outperform" rating on the stock.
11/6
08:06 am
trda
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at HC Wainwright from $18.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at HC Wainwright from $18.00 to $20.00. They now have a "buy" rating on the stock.
11/6
08:05 am
trda
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/5
10:05 am
trda
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/5
07:00 am
trda
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
Medium
Report
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
10/9
07:00 am
trda
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
Low
Report
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society